CAR-T cell therapy for lupus that hasn't improved with standard treatments
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new treatment called CAR-T cells, which are specially trained immune cells designed to target and destroy lupus-causing cells. It is for adults with active lupus that has not responded to at least two standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 50 years old.
- You have a confirmed diagnosis of lupus that is currently active.
- Your lupus has not improved or you cannot take at least two standard treatments (like steroids, mycophenolate, or rituximab).
- Your heart, lungs, kidneys, and liver are working well enough to safely receive this therapy.
- You are not pregnant, breastfeeding, or planning to become pregnant during the trial and for 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment called rapcabtagene autoleucel for people with active lupus or lupus nephritis that hasn't improved with at least two standard therapies. It aims to reduce disease activity and may offer a new option for hard-to-treat cases.
This trial tests whether a type of immune cell therapy called CAR-T can help people with active lupus that hasn't responded well to standard treatments. It aims to reduce disease activity and improve symptoms.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
This trial tests a new CAR-T cell treatment for people with lupus who still have moderate to severe symptoms despite trying standard medications. It aims to quickly stop the immune system from attacking the body.
This trial tests a treatment called CD19/BCMA CAR-T for people with lupus (SLE) that has not improved with standard treatments. The therapy uses your own immune cells, modified to target and calm overactive immune cells, aiming to reduce disease activity.
This study tests a new type of immune cell therapy (CAR-T cells) designed to target and reduce the immune cells driving lupus in patients whose disease hasn't responded to standard treatments. Researchers will first identify which specific immune cells are causing your lupus, then engineer your own immune cells to fight them.
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.